Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Block listing return

3 Jan 2023 17:19

RNS Number : 5695L
Oxford Biomedica PLC
03 January 2023
 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Employee Share Option Scheme

Period of return:

From:

1 July 2022

To:

31 December 2022

Balance of unallotted securities under scheme(s) from previous return:

336,239

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

4,665

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

331,574

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Long Term Incentive Plan

Period of return:

From:

1 July 2022

To:

31 December 2022

Balance of unallotted securities under scheme(s) from previous return:

519,668

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

180,349

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

339,319

 

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Deferred Bonus Plan

Period of return:

From:

1 July 2022

To:

31 December 2022

Balance of unallotted securities under scheme(s) from previous return:

206,835

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

4,390

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

202,445

 

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

Sharesave Scheme

Period of return:

From:

1 July 2022

To:

31 December 2022

Balance of unallotted securities under scheme(s) from previous return:

331,484

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

331,484

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRBJMRTMTBMBPJ
Date   Source Headline
28th May 20217:00 amEQSOxford Biomedica (OXB): Driving innovation in a thriving CGT industry
28th May 20217:00 amRNSBlock Listing Application
28th May 20217:00 amRNSResult of AGM
27th May 20217:00 amRNSBoard Change
25th May 20219:21 amRNSDirector/PDMR Shareholding
21st May 202112:46 pmRNSPDMR Dealing
20th May 202111:42 amRNSPDMR Dealings
18th May 20217:00 amRNSOxford Biomedica upgrades financial guidance
10th May 202110:54 amRNSHolding(s) in Company
4th May 202110:29 amRNSTotal Voting Rights
4th May 202110:27 amRNSHoldings in Company
27th Apr 20212:40 pmRNS2020 Annual report and Accounts & AGM Notification
26th Apr 202112:32 pmRNSHolding(s) in Company
15th Apr 20217:00 amRNSFull year results
6th Apr 20217:00 amRNSOXB signs Agreement with Boehringer Ingelheim
1st Apr 202111:04 amRNSTotal Voting Rights
30th Mar 202110:22 amRNSHolding(s) in Company
19th Mar 20217:01 amRNSUpdate on Sanofi Collaboration & License Agreement
15th Mar 202110:03 amRNSNotice of Preliminary Results
1st Mar 20219:36 amRNSTotal Voting Rights
26th Feb 202110:46 amRNSPDMR Dealings / Market Share sale
5th Feb 20211:22 pmRNSHoldings in Company
3rd Feb 20217:00 amRNSBoard Changes
1st Feb 20219:47 amRNSTotal Voting Rights
4th Jan 20212:09 pmRNSBlock Listing Return
4th Jan 20211:41 pmRNSTotal Voting Rights
30th Dec 20209:03 amRNSOXB notes AZ vaccine has been authorised in the UK
1st Dec 202012:17 pmRNSDirector Dealings
1st Dec 20209:02 amRNSTotal Voting Rights
23rd Nov 20208:47 amRNSOXB notes AZD1222 met primary efficacy endpoint
23rd Nov 20207:00 amRNSNon-Executive Director Appointment
9th Nov 20207:00 amRNSOXB and PhoreMost enter gene therapy collaboration
2nd Nov 20209:02 amRNSTotal Voting Rights
30th Oct 20207:00 amRNSAxovant update on AXO-Lenti-PD and virtual R&D day
23rd Oct 202010:27 amRNSDirector Purchase
12th Oct 20205:38 pmRNSHolding(s) in Company
6th Oct 202012:46 pmRNSAxovant update on 2nd cohort of SUNRISE-PD trial
6th Oct 20207:00 amRNSOXB receives approval for fourth suite in Oxbox
5th Oct 202010:59 amEQSEdison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
2nd Oct 202011:52 amRNSTotal Voting Rights
29th Sep 20203:51 pmRNSDirector Dealings
24th Sep 20209:36 amRNSDirector/PDMR Shareholding
22nd Sep 202012:54 pmRNSDirector/PDMR Shareholding
17th Sep 20207:00 amRNSInterim Results
1st Sep 20209:33 amRNSTotal Voting Rights
1st Sep 20207:00 amRNSMaster Supply and Development Agreement with AZ
27th Aug 20207:00 amRNSNotice of Interim Results
25th Aug 20204:46 pmRNSBlock listing Application
3rd Aug 20209:41 amRNSTotal Voting Rights
3rd Aug 20207:00 amRNSOXB signs DMLA with Beam Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.